Skip to main content
Sale!

GLP2-TZ 10mg

Original price was: $90.00.Current price is: $85.00.

**DISCONTINUING Jan 1st 2026**

GLP-2 TRZ 10mg dual GIP/GLP-1 receptor agonist for in vitro studies.

Out of stock

Category:

Description

GLP-2 TRZ | 10mg

For In Vitro Research Use Only – Not for Human or Veterinary Use

 

Specifications:
  • Quantity: 10mg
  • Form: Lyophilized Powder
  • Purity: >99% (HPLC Verified)
  • Molecular Weight: ~4812.6 g/mol
Intended Use:

Strictly for in vitro laboratory research. Not for use in humans or animals. Not intended for food, drug, or diagnostic purposes.

Legal Disclaimer:

This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Use is restricted to qualified research institutions.

Terms of Sale:

All sales from Onyx Research are final. Buyer affirms they are a trained laboratory professional and takes full responsibility for safe handling, storage, and regulatory compliance.

There are no reviews yet.

Be the first to review “GLP2-TZ 10mg”

Your email address will not be published. Required fields are marked *

FDA Disclaimer

The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

Onyx Research is a chemical supplier. Onyx Research is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Onyx Research is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

THE PRODUCTS WE OFFER ARE NOT INTENDED FOR HUMAN USE. THEY ARE INTENDED FOR IN-VITRO AND PRE-CLINICAL RESEARCH PURPOSES ONLY. THE CUSTOMER ACKNOWLEDGES THAT THERE ARE RISKS IN THE HANDLING, USE, AND DISTRIBUTION OF THESE PRODUCTS, AND CERTIFIES THAT IT HAS THE PROPER EQUIPMENT, FACILITIES, AND PERSONNEL FOR MANAGING THOSE RISKS; AND THE CUSTOMER KNOWINGLY ACCEPTS THESE RISKS.